Clinical Trial Update: A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma [Phase 1]

View source ↗

Summary

The Phase 1 pharmacokinetics study assessing the effect of ketoconazole on vemurafenib in BRAFV600 mutation–positive metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Ketoconazole (Ketoconazole)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma, Neoplasms | Phase 1 | Status: WITHDRAWN